Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites
Autore:
Spina, E; Avenoso, A; Scordo, MG; Ancione, M; Madia, A; Levita, A;
Indirizzi:
Univ Messina, Policlin Univ, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, I-98125 Messina, Italy Univ Messina Messina Italy I-98125 harmacol Sect, I-98125 Messina, Italy Azienda USL 5, Ctr Mental Hlth, Messina, Italy Azienda USL 5 Messina Italy enda USL 5, Ctr Mental Hlth, Messina, Italy Barcellona PG, Hosp Psychiat, Messina, Italy Barcellona PG Messina Italy arcellona PG, Hosp Psychiat, Messina, Italy
Titolo Testata:
THERAPEUTIC DRUG MONITORING
fascicolo: 6, volume: 23, anno: 2001,
pagine: 675 - 678
SICI:
0163-4356(200112)23:6<675:NEOROP>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
MAJOR METABOLITES; LIQUID-CHROMATOGRAPHY; ULTRAVIOLET DETECTION; HEALTHY-VOLUNTEERS; SCHIZOPHRENIA; 9-HYDROXYRISPERIDONE; PHARMACOKINETICS; FLUVOXAMINE; FLUOXETINE; SERUM;
Keywords:
reboxetine; clozapine; risperidone; drug interaction; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Spina, E Univ Messina, Policlin Univ, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Torre Biol,5 Piano, I-98125 Messina, Italy Univ Messina TorreBiol,5 Piano Messina Italy I-98125 ina, Italy
Citazione:
E. Spina et al., "No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites", THER DRUG M, 23(6), 2001, pp. 675-678

Abstract

The effect of reboxetine on steady-state plasma concentrations of the atypical antipsychotics clozapine and risperidone was studied in 14 patients with schizophrenia or schizoaffective disorder with associated depressive symptoms. Seven patients stabilized on clozapine therapy (250-500 mg/day) and seven receiving risperidone (4-6 mg/day) were given additional reboxetine (R mg/day). After 4 weeks of reboxetine therapy, mean plasma concentrations of clozapine, norclozapine, and risperidone active moiety (sum of concentrations of risperidone and 9-hydroxyrisperidone) increased slightly but not significantly by 5%, 2%, and 10%, respectively. The mean plasma clozapine/norclozapine and risperidone/9-hydroxyrisperidone ratios were not modified during reboxetine treatment. Reboxetine coadministration with either clozapine or risperidone was well tolerated. These findings indicate that reboxetine has minimal effects on the metabolism of clozapine and risperidone and may be added safely to patients receiving maintenance treatment with these two antipsychotics.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/01/20 alle ore 20:10:59